Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of navenibart for prophylaxis of hereditary angioedema attacks
NL-OMON59417Phase 3Completed
- Sponsor
- Astria Therapeutics
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in hereditary angioedema (HAE) comparing Navenibart with Placebo (2 arms). Primary endpoint: Time-normalized investigator-confirmed HAE attacks. Started Sep 2025; status: completed.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON59417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59417.